A detailed history of Trustmark National Bank Trust Department transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Trustmark National Bank Trust Department holds 38,370 shares of BMY stock, worth $2.2 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
38,370
Previous 57,591 33.38%
Holding current value
$2.2 Million
Previous $2.39 Million 16.98%
% of portfolio
0.15%
Previous 0.19%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$39.66 - $51.75 $762,304 - $994,686
-19,221 Reduced 33.38%
38,370 $1.99 Million
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $342,567 - $450,997
-8,511 Reduced 12.88%
57,591 $2.39 Million
Q1 2024

May 10, 2024

SELL
$47.98 - $54.4 $1.15 Million - $1.3 Million
-23,937 Reduced 26.59%
66,102 $3.58 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $967,466 - $1.15 Million
19,956 Added 28.47%
90,039 $4.62 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $223,571 - $249,987
-3,862 Reduced 5.22%
70,083 $4.07 Million
Q2 2023

Aug 10, 2023

SELL
$63.71 - $70.74 $300,520 - $333,680
-4,717 Reduced 6.0%
73,945 $4.73 Million
Q1 2023

May 10, 2023

SELL
$65.71 - $74.53 $1.72 Million - $1.96 Million
-26,251 Reduced 25.02%
78,662 $5.45 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $16,914 - $20,029
247 Added 0.24%
104,913 $7.55 Million
Q3 2022

Nov 09, 2022

SELL
$0.13 - $76.84 $437 - $258,489
-3,364 Reduced 3.11%
104,666 $7.44 Million
Q2 2022

Aug 11, 2022

BUY
$72.62 - $79.98 $495,486 - $545,703
6,823 Added 6.74%
108,030 $8.32 Million
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $92,773 - $111,243
1,509 Added 1.51%
101,207 $7.39 Million
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $37,755 - $44,014
704 Added 0.71%
99,698 $6.22 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $420,107 - $492,101
-7,100 Reduced 6.69%
98,994 $5.86 Million
Q2 2021

Aug 11, 2021

BUY
$61.91 - $67.42 $95,527 - $104,029
1,543 Added 1.48%
106,094 $7.09 Million
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $792,307 - $891,112
13,352 Added 14.64%
104,551 $6.6 Million
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $753,911 - $854,319
13,057 Added 16.71%
91,199 $5.66 Million
Q3 2020

Nov 13, 2020

BUY
$57.43 - $63.64 $47,896 - $53,075
834 Added 1.08%
78,142 $4.71 Million
Q2 2020

Aug 12, 2020

BUY
$54.82 - $64.09 $235,945 - $275,843
4,304 Added 5.9%
77,308 $4.55 Million
Q1 2020

May 14, 2020

BUY
$46.4 - $67.43 $132,796 - $192,984
2,862 Added 4.08%
73,004 $4.07 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $227,350 - $296,557
4,620 Added 7.05%
70,142 $4.5 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $57,782 - $68,509
-1,351 Reduced 2.02%
65,522 $3.32 Million
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $67,599 - $74,750
-1,515 Reduced 2.22%
66,873 $3.03 Million
Q1 2019

May 13, 2019

SELL
$45.12 - $53.8 $125,704 - $149,886
-2,786 Reduced 3.91%
68,388 $3.26 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $174,512 - $226,300
3,579 Added 5.29%
71,174 $3.7 Million
Q3 2018

Feb 22, 2019

SELL
$55.19 - $62.25 $581,537 - $655,928
-10,537 Reduced 13.49%
67,595 $4.2 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $538,709 - $607,622
9,761 Added 14.28%
78,132 $4.85 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $206,162 - $256,958
4,080 Added 6.35%
68,371 $3.78 Million
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $282,043 - $324,688
4,707 Added 7.9%
64,291 $4.07 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $701,477 - $764,791
11,703 Added 24.44%
59,584 $3.65 Million
Q3 2017

Nov 09, 2017

BUY
$55.23 - $63.74 $2.64 Million - $3.05 Million
47,881
47,881 $3.05 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Trustmark National Bank Trust Department Portfolio

Follow Trustmark National Bank Trust Department and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trustmark National Bank Trust Department, based on Form 13F filings with the SEC.

News

Stay updated on Trustmark National Bank Trust Department with notifications on news.